Related Experiment Videos
Rapamycin reduces neointima formation during vascular injury.
M Hilker1, M Buerke, M Guckenbiehl
1Department of Thoracic and Cardiovascular Surgery, Johannes Gutenberg University, Mainz, Germany. hilker@mail.uni-mainz.de
VASA. Zeitschrift Fur Gefasskrankheiten
|April 8, 2003
Summary
Rapamycin significantly reduced smooth muscle cell proliferation and extracellular matrix synthesis in vascular injury models. This suggests rapamycin
Area of Science:
- Vascular Biology
- Pharmacology
- Cell Biology
Background:
- Vascular smooth muscle cell (SMC) proliferation and migration are key in bypass graft disease and restenosis.
- Growth factors drive SMC proliferation and extracellular matrix (ECM) synthesis.
- Rapamycin is a known proliferation inhibitor.
Purpose of the Study:
- To investigate the effect of rapamycin on SMC proliferation and ECM synthesis.
- To evaluate rapamycin's efficacy in a rabbit vascular injury model and human SMC culture.
Main Methods:
- Rapamycin or vehicle administered via infusion-balloon catheter during vascular injury in rabbits.
- Intima/media ratio assessed histologically; protein expression analyzed by 2D gel electrophoresis.
- In vitro studies measured rapamycin's dose- and time-dependent effects on human SMC proliferation.
Main Results:
- Rapamycin significantly reduced the intima/media ratio in rabbits compared to controls (p < 0.05).
- Rapamycin markedly decreased ECM synthesis (lamin, vimentin) post-vascular injury.
- In vitro, rapamycin dose-dependently inhibited human SMC proliferation (1 nm-100 nm).
Conclusions:
- Rapamycin reduces SMC proliferation and ECM synthesis following vascular injury.
- These findings highlight the role of protein synthesis inhibition in vascular repair.
- Rapamycin demonstrates therapeutic potential for preventing vascular proliferative diseases.